BPC-157 vs. TB-500: A Research Comparison

BPC-157 and TB-500 are the two peptides most frequently compared in the tissue-repair and soft-tissue research literature. Both have been characterized in animal studies of musculoskeletal, vascular, and mucosal repair, and both appear together in the preclinical literature on combined-mechanism wound and tendon models. They are, however, structurally and mechanistically different compounds: BPC-157 is a 15-amino-acid pentadecapeptide derived from a fragment of body protection compound originally isolated from human gastric juice, while TB-500 is a 17-amino-acid synthetic fragment corresponding to the actin-binding region of thymosin beta-4 (TB4), a 43-amino-acid endogenous protein.

For researchers planning in vitro or animal-study work involving angiogenesis, fibroblast migration, endothelial cell biology, gastrointestinal mucosal models, or tendon and ligament repair models, BPC-157 and TB-500 are different research tools with overlapping but distinct experimental utility. This article compares them on the dimensions that matter for research design: structure and biochemistry, receptor and pathway pharmacology, animal-study literature, CoA standards, storage, and selection criteria for animal-study design.

Both are described here strictly for in vitro experimentation and animal-study use, not for human consumption. Nothing in this article should be read as a recommendation for human use, a therapeutic claim, or a dosing recommendation.

Quick reference

| Field | BPC-157 | TB-500 | |—|—|—| | CAS | 137525-51-0 | 77591-33-4 | | Origin | Pentadecapeptide derived from a partial sequence of body protection compound, originally isolated from human gastric juice | Synthetic 17-amino-acid fragment derived from the actin-binding region of thymosin beta-4 (TB4) | | Sequence length | 15 amino acids | 17 amino acids (synthetic fragment); full TB4 is 43 amino acids | | Sequence | Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val | Actin-binding fragment of TB4 spanning the central LKKTETQ motif and flanking residues | | Molecular weight (approx., free base) | ~1419.5 Da | ~889 Da (synthetic fragment); full TB4 ~4960 Da | | Form | Lyophilized white powder | Lyophilized white powder | | Primary pathway (animal-study literature) | VEGFR2 / FAK-paxillin / NO synthesis modulation; angiogenic and mucosal repair models | G-actin sequestration via actin-binding domain; endothelial migration, anti-inflammatory cytokine modulation | | Strongest published research context | Gastrointestinal mucosal repair, tendon and ligament animal models, vascular response | Cardiac and endothelial migration, corneal and dermal wound models, soft-tissue repair animal models | | Development status (mid-2026) | Investigational; no approved human indication | Investigational; full TB4 (under development codes such as RGN-259) has been studied in human clinical trials for ophthalmic indications; “TB-500” itself remains a research compound |

A research-grade CoA for either compound should report HPLC purity ≥ 99.0%, mass spectrometry confirmation within ±0.5 Da of theoretical, net peptide content, lot number, manufacturing date, and amino acid sequence. Any reputable research-supply vendor should publish the CoA per lot; verify that the lot number on the vial resolves to a downloadable PDF before use.

Structural and biochemical differences

The two compounds differ at every structural level — length, composition, origin, and mass.

BPC-157

BPC-157 is a 15-amino-acid pentadecapeptide with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. It corresponds to a partial sequence of a larger native molecule referred to in the original Sikiric-group publications as “body protection compound,” isolated from human gastric juice. The triple-proline motif (positions 3–5) and the central Asp-Asp residues contribute to its conformational stability in aqueous solution, and the foundational literature has reported notable stability of BPC-157 in gastric and aqueous environments compared with many small peptides [Sikiric P et al., Curr Neuropharmacol 2016, DOI 10.2174/1570159X13666160502153022].

Reported molecular weight is approximately 1419.5 Da (free base). A clean ESI-MS spectrum should show the [M+H]⁺ singly charged ion at ~1420.5 m/z; doubly charged [M+2H]²⁺ at ~710.8 m/z is also commonly observed.

TB-500

TB-500 is a 17-amino-acid synthetic peptide derived from the actin-binding region of thymosin beta-4. Full-length thymosin beta-4 is a 43-amino-acid, ~4960 Da endogenous protein that participates in cellular G-actin sequestration and a broad range of regenerative-biology pathways. TB-500 isolates and reproduces the central actin-binding motif (the LKKTETQ region and flanking residues) into a much smaller synthetic peptide of ~889 Da.

This distinction is important: in the vendor market, the term “TB-500” is used inconsistently. Some vendors sell the 17-amino-acid synthetic fragment (the historically described “TB-500”); others sell the full 43-amino-acid recombinant or synthetic TB4 under the same product name. The two have ~4071 Da of mass difference and are not interchangeable research tools. A researcher must confirm which compound the CoA describes — the singly charged [M+H]⁺ should appear at ~890 m/z for the synthetic fragment, or ~4961 m/z (with multiple charge states) for full-length TB4. We discuss this verification step in the CoA section below.

For the remainder of this article, “TB-500” refers to the synthetic ~889 Da fragment unless otherwise specified.

Mechanism and pathway pharmacology

BPC-157 and TB-500 are mechanistically dissimilar at the molecular level, even though both appear in soft-tissue repair animal-study literature. Neither is a classical receptor agonist in the way that GLP-1R agonists or melanocortin agonists are.

BPC-157 pathways

The BPC-157 animal-study literature describes effects on several signaling pathways:

VEGFR2 upregulation — BPC-157 has been reported to modulate vascular endothelial growth factor receptor 2 expression in animal-study models of vascular response and angiogenesis. The Sikiric group’s reviews aggregate this work across multiple animal models [Sikiric P et al., Curr Neuropharmacol 2016].
FAK-paxillin axis — focal adhesion kinase (FAK) and paxillin are central to cellular adhesion and migration; animal-study work in tendon-derived cell models reports BPC-157 effects on this axis [Chang CH et al., J Appl Physiol 2011, DOI 10.1152/japplphysiol.00945.2010].
Nitric oxide (NO) synthesis modulation — animal-study models of vascular and gastric mucosal response report BPC-157 interaction with the NO-synthase system.
Growth-hormone receptor expression — animal-study work in tendon fibroblast models reports BPC-157 effects on growth hormone receptor expression [Chang CH et al., 2011].

The collective picture from the BPC-157 animal-study literature is a peptide that modulates several pathways relevant to angiogenesis, cellular adhesion and migration, and vascular response — relevant in animal-study contexts of mucosal repair, tendon repair, and vascular models. No specific high-affinity receptor for BPC-157 has been characterized in the peer-reviewed literature; the mechanism is described as multi-pathway.

TB-500 pathways

The TB-500 pathway picture is more singular at the molecular level. The peptide’s primary biochemical activity is G-actin sequestration via its actin-binding domain — the LKKTETQ motif binds monomeric G-actin and modulates actin polymerization dynamics, which is central to cellular migration in many cell types [Goldstein AL et al., Expert Opin Biol Ther 2012, DOI 10.1517/14712598.2012.634793].

Downstream of this primary biochemical activity, the TB-500 / TB4 animal-study literature reports:

Endothelial cell migration — cell-migration assays and animal-study wound models report TB-500 / TB4 effects on endothelial migration and capillary formation.
Cardiomyocyte migration and survival — animal-study cardiac models report TB4 effects on cardiomyocyte response after experimental injury [Crockford D et al., Ann N Y Acad Sci 2010].
Anti-inflammatory cytokine modulation — animal-study and in vitro work report TB4 modulation of inflammatory cytokine profiles, including reduced expression of pro-inflammatory mediators in some experimental models.
Corneal and dermal wound repair models — TB4-based compounds have been studied in ophthalmic indications; the related compound RGN-259 (a TB4-based formulation) has been studied in human ophthalmic clinical trials, which is a different regulatory pathway from research-grade TB-500.

The collective picture from the TB-500 animal-study literature is a peptide whose primary biochemical activity (G-actin binding) underlies a range of downstream effects on cellular migration, vascular response, and inflammatory cytokine profiles in animal-study models.

Mechanistic comparison

The two peptides act through different molecular biology:

BPC-157’s animal-study effects are described as multi-pathway modulation (VEGFR2, FAK-paxillin, NO synthesis) without a defined high-affinity receptor.
TB-500’s animal-study effects are anchored in a single primary biochemical activity (G-actin sequestration) with broader downstream consequences.

This is one reason both compounds appear in the combined-mechanism animal-study literature — they engage different pathways relevant to soft-tissue repair, which is the rationale for the BPC+TB blend research convenience product (described below).

Animal-study findings reported in the literature

Both compounds have published animal-study literatures. As with all preclinical work, these findings are research observations and do not establish safety or efficacy in any species, including humans.

BPC-157 animal-study literature

Published animal-study findings include:

Gastrointestinal mucosal models — the largest single body of BPC-157 animal-study literature concerns gastric, esophageal, and intestinal mucosal repair models. The Sikiric group has reported BPC-157 effects in animal-study models of induced gastric and intestinal injury across multiple publications [reviewed in Sikiric P et al., Curr Neuropharmacol 2016].
Tendon and ligament models — animal-study work in Achilles tendon transection models and rotator-cuff models has reported effects on healing markers and biomechanical outcomes [Chang CH et al., 2011; Chang CH et al., J Orthop Res 2014].
Vascular response — animal-study models of vessel occlusion and ischemia–reperfusion report BPC-157 effects on vessel recruitment and tissue response.
Central nervous system models — animal-study models of nigrostriatal and central nervous system response report BPC-157 effects on dopaminergic and serotonergic markers in some experimental designs.

TB-500 / TB4 animal-study literature

Published animal-study findings include:

Cardiac repair models — animal-study models of experimental myocardial injury report TB4 effects on cardiomyocyte response and cardiac function markers [Bock-Marquette I et al., Nature 2004].
Dermal and corneal wound models — animal-study wound-healing models report TB4 effects on wound closure rate and re-epithelialization markers.
Endothelial migration assays — in vitro and animal-study work reports TB4 / TB-500 effects on endothelial cell migration and capillary formation.
Anti-inflammatory cytokine profiles — animal-study work reports modulation of inflammatory cytokine expression in several experimental designs [Goldstein AL et al., 2012].

The TB-500 animal-study literature is somewhat narrower at the molecular level (anchored in actin biology) but broad in tissue context, spanning cardiac, vascular, dermal, and ophthalmic experimental models.

Research design considerations

For researchers choosing between the two compounds — or designing a combined-mechanism animal-study experiment — the practical questions:

Use BPC-157 when:

The research question concerns gastrointestinal mucosal repair models, where the BPC-157 literature is deepest.
The animal-study design centers on the VEGFR2 / angiogenesis axis or FAK-paxillin cellular adhesion biology.
The model is a tendon, ligament, or musculoskeletal repair model, where the BPC-157 published animal-study work is well-represented.
The research design needs a peptide with notable stability in aqueous and gastric environments.

Use TB-500 when:

The research question concerns actin polymerization dynamics or G-actin sequestration biology specifically.
The animal-study model is centered on endothelial cell migration, cardiomyocyte response, or dermal wound re-epithelialization.
The design requires a peptide with a defined primary biochemical interaction (actin binding) rather than multi-pathway modulation.
The research context is cardiac, vascular, or ophthalmic experimental modeling.

Use both when:

The animal-study design aims to interrogate combined-mechanism soft-tissue repair, where the multi-pathway BPC-157 profile and the actin-binding TB-500 profile address different aspects of the same model.
The research question concerns the marginal contribution of one pathway on top of the other.
The model is a tendon repair, ligament repair, or composite soft-tissue model where both literatures are represented.

For animal-study designs that require both compounds together at consistent ratios, the BPC-157 + TB-500 blend is offered as a research convenience product — a single lyophilized vial containing both peptides at characterized ratios, eliminating two separate reconstitution and dilution steps. The blend is intended only for research designs that have already established the rationale for combined-mechanism animal-study work; it does not displace single-compound work for studies that aim to isolate the contribution of one peptide.

What to verify on the CoA

Both compounds are peptides of modest size and synthesis complexity. The standard CoA verification points covered in How to Read a Peptide Certificate of Analysis apply to both: HPLC purity ≥ 99.0%, mass spectrometry confirmation within ±0.5 Da, net peptide content, lot number, manufacturing date.

Beyond the standard checklist, compound-specific verification points:

For BPC-157:

Mass spectrum confirming ~1419.5 Da, with [M+H]⁺ at ~1420.5 m/z and doubly charged [M+2H]²⁺ at ~710.8 m/z visible on the spectrum.
Sequence confirmation — the 15-amino-acid sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val should be reported on the CoA. The triple-proline motif is a sequence-verification anchor point.
HPLC purity ≥ 99.0%, with minor peaks below 1% characterized where possible.
Net peptide content reported, with counterion identified (typically acetate or trifluoroacetate for research-grade material).
Lot number matching the vial.

For TB-500:

Mass spectrum confirming ~889 Da, with [M+H]⁺ at ~890 m/z. This is the most important verification point for TB-500. Some vendor products labeled “TB-500” are in fact the full-length 43-amino-acid thymosin beta-4 (~4960 Da). The two compounds have very different masses, very different per-mg molarities, and are not interchangeable in an animal-study design. A researcher must confirm from the CoA mass spectrum whether the supplied compound is the ~889 Da synthetic fragment or the ~4960 Da full-length protein.
Sequence confirmation — the actin-binding fragment sequence should be reported on the CoA, with explicit indication of whether the compound is the 17-amino-acid fragment or full TB4.
HPLC purity ≥ 99.0%, with minor peaks below 1% characterized where possible.
Net peptide content reported, with counterion identified.
Lot number matching the vial.

The TB-500 mislabeling issue is the single most consequential CoA verification step in this comparison and should not be skipped. A quality vendor publishes per-lot CoAs for both compounds; the mass spectrum is the definitive identity check., with the mass spectrum visible on the document.

Storage and handling

Both compounds are supplied lyophilized, and the handling protocols are essentially identical.

Lyophilized storage: room temperature, away from light, for typical short-term research timeframes (weeks to a few months). For longer-term storage, freezer storage at -20°C in a low-humidity environment (sealed vial, desiccant present) extends shelf life for multi-year storage. Both peptides are relatively stable in the lyophilized state, with BPC-157 in particular reported to have notable stability versus many small peptides.

Reconstituted storage: refrigerate at 2–8°C, use within 28 days. Bacteriostatic water (0.9% benzyl alcohol) is the standard reconstitution medium for multi-dose research vials. Add the reconstitution medium slowly down the inside wall of the vial. Do not shake. Gentle swirling or inversion only. Do not freeze and thaw reconstituted solutions; aliquot before any freezer storage if longer-term reconstituted storage is required, and discard any aliquot that has been thawed.

Blend handling: the BPC-157 + TB-500 blend is reconstituted using the same protocol as the single-compound vials. Volume calculations should account for the combined mg content stated on the CoA, not the individual peptide content; the CoA for the blend reports the per-vial mass of each peptide as well as the total.

For the full protocol comparison, see the storage protocol guide.

Summary

BPC-157 and TB-500 are different research tools with overlapping but distinct experimental utility in soft-tissue repair animal-study designs. BPC-157 is a 15-amino-acid pentadecapeptide derived from a partial sequence of body protection compound, with a multi-pathway animal-study mechanism profile spanning VEGFR2, FAK-paxillin, and NO-synthesis modulation; the literature is deepest in gastrointestinal mucosal, tendon, and ligament animal models. TB-500 is a 17-amino-acid synthetic fragment of thymosin beta-4, with a defined primary biochemical activity (G-actin sequestration); the literature is deepest in cardiac, endothelial migration, and dermal/corneal animal-study models.

The two compounds are not interchangeable; selection between them depends on the research question, the model system, and the molecular pathway of interest. For combined-mechanism animal-study designs that engage both literatures, the BPC-157 + TB-500 blend is offered as a research convenience product.

CoA verification before use is essential for both: HPLC purity ≥ 99.0%, mass spectrometry confirmation of the expected mass within ±0.5 Da, net peptide content, lot number matching the vial, and lot-specific accessibility through the vendor’s published verification system. For TB-500 specifically, the mass spectrum is the verification point that distinguishes the synthetic fragment from full-length thymosin beta-4 — a distinction that some vendor catalogs blur.

Selected peer-reviewed sources

Sikiric P, Seiwerth S, Rucman R, et al. “Brain-gut Axis and Pentadecapeptide BPC 157: Theoretical and Practical Implications.” Curr Neuropharmacol (2016). DOI 10.2174/1570159X13666160502153022. Foundational BPC-157 review aggregating animal-study work across multiple models.
Chang CH, Tsai WC, Lin MS, Hsu YH, Pang JS. “The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration.” J Appl Physiol (2011). DOI 10.1152/japplphysiol.00945.2010. https://pubmed.ncbi.nlm.nih.gov/21030673/
Chang CH, Tsai WC, Hsu YH, Pang JS. “Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts.” Molecules (2014). Tendon fibroblast animal-study work.
Goldstein AL, Hannappel E, Sosne G, Kleinman HK. “Thymosin β4: a multi-functional regenerative peptide. Basic properties and clinical applications.” Expert Opin Biol Ther (2012). DOI 10.1517/14712598.2012.634793. Foundational TB4 / TB-500 review covering biochemical activity and animal-study findings across tissue contexts.
Crockford D, Turjman N, Allan C, Angel J. “Thymosin β4: Structure, function, and biological properties supporting current and future clinical applications.” Ann N Y Acad Sci (2010). https://pubmed.ncbi.nlm.nih.gov/20955328/
Bock-Marquette I, Saxena A, White MD, Dimaio JM, Srivastava D. “Thymosin β4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair.” Nature (2004). Foundational animal-study cardiac repair paper for TB4.
Sikiric P, Skrtic A, Gojkovic S, et al. “Cytoprotective gastric pentadecapeptide BPC 157 resolves major vessel occlusion disturbances, ischemia-reperfusion injury and related lesions.” World J Gastroenterol (2022). Vascular response animal-study review for BPC-157.
Huang T, Zhang K, Sun L, et al. “Body protective compound-157 enhances alkali-burn wound healing in vivo and promotes proliferation, migration, and angiogenesis in vitro.” Drug Des Devel Ther (2015). https://pubmed.ncbi.nlm.nih.gov/26648692/
Philp D, Goldstein AL, Kleinman HK. “Thymosin β4 promotes angiogenesis, wound healing, and hair follicle development.” Mech Ageing Dev (2004). Background animal-study reference for TB4 wound and angiogenic biology.

Research Use Only — Disclaimer

BPC-157, TB-500, related blend preparations, and all peptides discussed on this page are described for laboratory and research purposes only. They are intended exclusively for in vitro experimentation and for use in animal studies under appropriate institutional oversight. They are not drugs, dietary supplements, cosmetics, or food additives. They are not for human consumption, not for treatment of any injury or condition, not for athletic or recovery use in humans, and not for any therapeutic, diagnostic, preventive, or palliative purpose. The research-grade material described on this page is not equivalent to any approved or compounded human pharmaceutical product.

Nothing on this page constitutes medical advice. No statement on this page should be interpreted as a recommendation, claim, or representation that any peptide compound is safe, effective, or appropriate for any use in humans, including for tissue repair, injury recovery, tendon or ligament conditions, gastrointestinal conditions, or any other indication. Animal-study findings reported in the peer-reviewed literature are described for research context only and do not establish safety or efficacy in humans.

Buyers must be at least 21 years of age and must agree to use products strictly for research purposes.